Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Merck KGaA
 More »

  • GEN | Biolinks
    ... Technologies, Inc Merck & Co. Merck KGaA Merck Millipore Merck Serono SA Merrimack Pharmaceuticals, Inc Mersana Therapeutics, Inc Metabolex, Inc Metabolic Solutions Development Co. ...
  • EMD Serono Expanding R&D Hub in Billerica, MA
    Industry Snapshot 2012. Billerica houses one of four regional R&D hubs for Merck KGaA; the other three are in Beijing, Tokyo, and Darmstadt, Germany. Company says ...
    4-18-2013
  • Cetrotide Manufacturing Rights Transferred to Merck Serono
    In addition, Aeterna Zentaris entered into a transitional services agreement with Merck KGaA under which the company will, during a 36-month period, provide various transition ...
    4-17-2013
  • Top 10 Biopharma Layoffs of 2012
    Costs & charges: $149 million in 2012 for restructuring of U.S. pharmaceuticals operations. 4. Merck KGaA Total workforce reduction: 1,600 jobs (4)* Locations: 1,100 positions in ...
    3-15-2013
  • Merck KGaA Offers Sunny Forecast for 2013, 2014
    Merck KGaA says it expects "significant" increases in profits this year and 2014 but only modest increases in sales after months of cost cutting and an income tax break helped ...
    3-8-2013
  • Top 10 Biopharma Layoffs of 2012
    ... rounds, as well as plans to cut "several hundred" additional jobs in 2013. #4. Merck KGaA Total workforce reduction: 1,600 jobs 4 Locations: 1,100 positions in Germany; 500 ...
    2-15-2013
  • Progressive MS Therapy Sparks Deal Worth Up to $225M
    With the Opexa deal, Merck Serono jumps back into the increasingly crowded field of biopharma giants stepping up their activity in MS drugs. Back in 2011, parent Merck KGaA ended ...
    2-5-2013
  • Apeiron Out-Licenses Antibody-Based Immunotherapy
    to acquire rights to further develop and commercialize the immunocytokine hu14.18-IL2 from Merck KGaA, Germany in February 2011. Apeiron Out-Licenses Antibody-Based Immunotherapy
    1-18-2013
  • MS Research Gets $1.4M Boost
    committee comprised of Fast Forward staff and representatives from EMD Serono and Merck KGaA. The organizations that will receive funding under the Accelerating Commercial ...
    12-21-2012
  • Ablynx, Algeta Form Cancer Collaboration
    Ablynx has ongoing research collaborations and other "significant" partnerships with pharma giants that include Boehringer Ingelheim, Merck & Co., Merck KGaA, and Novartis. Ablynx ...
    11-21-2012
  • Funds Won for Oral T-Cell Cancer Vaccine Platform
    The firm was established in 2008 as a joint venture between Merck KGaA and BB Biotech Ventures, to develop VXM01. Swiss-German cancer vaccines firm Vaximm said its German ...
    10-2-2012
  • Dual-Antibody Anticancer Candidate Gets $25M Boost
    Merck KGaA is paying Symphogen €20 million (about $25 million) up front for an exclusive worldwide license to develop the latter's anticancer candidate Sym004, an antibody ...
    9-6-2012
  • Cell Culture Deal: Millipore Buying Biochrom
    Merck KGaA's life science division EMD Millipore will purchase Germany-based mammalian ... commercial drug materials," comments Robert Yates, head of the Merck Millipore division. ...
    8-22-2012
  • Top 25 Biotech Companies
    ... billion) 2011 Market Cap: $18.33 billion (A$17.454 billion) % Change: 15.2% #8. Merck KGaA 2012 Market Cap: $21.16 billion (6/30: 217,388,939 shares * price €78.72) 2011 ...
    8-17-2012
  • Millipore to Distribute Xeno-Free Osteogenic Medium
    Merck KGaA's life science division EMD Millipore negotiated a license to distribute ... Merck KGaA's life science division EMD Millipore negotiated a license to distribute ...
    8-14-2012

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll